Combining Pravastatin & Ezetimibe to Lower LDL - Quick Reference Sheet
evipedia.ai
← Back

Combining Pravastatin & Ezetimibe to Lower LDL

Created on 09/18/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Two oral medications lower cholesterol by unrelated routes: one slows liver production, one blocks gut absorption. Together they lower the cholesterol that drives artery disease further than either alone, and further than doubling the liver-acting drug. Evidence for preventing heart attacks and strokes is strong but borrowed from a different pairing. Harms are well characterised and mostly modest. (Full Review)

Protocol

Standard regimen
Pravastatin 20–40 mg + ezetimibe 10 mg once daily
Given as one regimen. Ezetimibe has no higher dose, so escalation happens on the pravastatin side only.
Relative timing
Both together, single administration
Ezetimibe's 22-hour half-life makes its timing irrelevant; co-administration is chosen for adherence and does not alter either agent's blood levels.
Best time of day
Evening
Cholesterol synthesis peaks overnight and pravastatin's short half-life makes timing matter. A fixed evening slot removes day-to-day variation in exposure.
Time to effect
LDL falls measurably
2 weeks
LDL falls measurably within two weeks, well before the new steady state is reached.
New steady state
4–6 weeks
When a follow-up lipid panel is informative.
Event-level benefit
Years
Fewer heart attacks and strokes accrue on a decade scale, not alongside the lipid change.

Benefits

Contraindications
  • Active liver disease, or unexplained persistent transaminase elevation at or above three times the upper limit of normal
  • Pregnancy, women planning pregnancy, and breastfeeding
  • Moderate or severe hepatic impairment (Child-Pugh Class B or C)
  • Known hypersensitivity to either agent, including prior angioedema or urticaria
  • Prior statin-attributed rhabdomyolysis, unless rechallenged under specialist supervision
Key Interactions
  • Cyclosporine
  • Fibrates (gemfibrozil, fenofibrate)
  • Bile acid sequestrants (cholestyramine, colesevelam, colestipol): ezetimibe at least two hours before or four hours after
  • Warfarin and other vitamin K antagonists
  • Colchicine, high-dose niacin, and macrolide antibiotics (erythromycin, clarithromycin)
  • Rifampin
  • Over-the-counter medications (orlistat)
  • Red yeast rice
  • Plant sterol and stanol supplements
  • Additive LDL-lowering supplements (psyllium, beta-glucan, berberine, bergamot)
  • Other lipid interventions (PCSK9 inhibitors: evolocumab, alirocumab; bempedoic acid, which caps pravastatin at 40 mg)

Risk & Side Effects

  • High: Muscle symptoms and, rarely, rhabdomyolysis; new-onset type 2 diabetes; liver enzyme elevation; small excess of bleeding stroke
  • Medium: Gastrointestinal symptoms; fatigue and reduced energy on exertion
  • Low: Cognitive complaints; reduced circulating coenzyme Q10; cancer incidence
  • Speculative: Gallstone formation
    •

Monitoring

Marker Target Why
LDL cholesterol <70 mg/dL with established artery disease; <100 mg/dL otherwise; <55 mg/dL at very high risk The direct target of both agents
Apolipoprotein B <80 mg/dL; <60 mg/dL at very high risk Counts atherogenic particles; tracks risk better than LDL when triglycerides are high
Non-HDL cholesterol <100 mg/dL; <130 mg/dL at lower risk Captures every cholesterol-carrying particle in one figure
Alanine aminotransferase (ALT) <25 U/L in men, <20 U/L in women Detects the hepatic injury that is the combination's defining contraindication
Creatine kinase (CK) Within the laboratory reference range, and stable against the individual's own baseline Confirms or excludes true muscle injury when symptoms appear
Glycated haemoglobin (HbA1c) 4.8–5.4% Detects the modest statin-associated drift toward diabetes
Thyroid-stimulating hormone (TSH) 0.5–2.5 mIU/L Untreated low thyroid function raises cholesterol and muscle-injury risk
Lipoprotein(a) <30 mg/dL (<75 nmol/L) A genetically fixed risk carrier that neither agent lowers, and that reframes the LDL target
Campesterol and sitosterol No established target; track the fall from the individual's own baseline Confirms the ezetimibe component is being absorbed and is working

Cadence: Baseline before starting; lipids and liver enzymes at 8–12 weeks after starting or any dose change, again at 6 months, then every 6–12 months once stable; glucose markers annually.

Qualitative Assessment

  • Muscle aching, cramping, tenderness or weakness, especially in the thighs and shoulders, and whether it tracks with dose changes
  • Energy on exertion, and whether a training session that was previously routine now feels unusually hard
  • Sleep quality and dream disturbance in the weeks after starting or changing the evening dose
  • Bowel habit, bloating and abdominal discomfort in the first month, the window in which ezetimibe-related symptoms appear
  • Subjective mental clarity and word-finding, recorded before starting so that any later change has a reference point
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.